Evidence map›Paper›PMID 39776642›Full record

ArticleFrontiers in pediatrics2024

Impact of metabolic-associated fatty liver disease on the cholesterol efflux capacity of high-density lipoproteins in adolescents with type 2 diabetes.

José Antonio Orozco Morales, Aída Xochitl Medina Urrutia, Margarita Torres Tamayo, Juan Reyes Barrera, Esteban Jorge Galarza, Juan Gabriel Juárez Rojas, Pilar Dies Suarez, Nahum Méndez Sánchez, Luis Enrique Díaz Orozco, Lubia Velázquez-López and 1 more

Abstract read
In one paragraph

Article in Frontiers in pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

José Antonio Orozco MoralesDepartment of Endocrinology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Aída Xochitl Medina UrrutiaDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Margarita Torres TamayoDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Juan Reyes BarreraDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Esteban Jorge GalarzaDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Juan Gabriel Juárez RojasDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Pilar Dies SuarezDepartment of Imaging, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.
Nahum Méndez SánchezFaculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Luis Enrique Díaz OrozcoFaculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Lubia Velázquez-LópezClinical Epidemiology Research Unit, Hospital Carlos Mac Gregor Sánchez Navarro, Mexican Social Security Institute (Instituto Mexicano del Seguro Social, IMSS), Mexico City, Mexico.
Patricia Medina BravoDepartment of Endocrinology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Type 2 diabetes (DM2) is an emerging disease in the pediatric population. DM2 is associated with metabolic-associated fatty liver disease (MAFLD). High-density lipoproteins (HDLs) are lipoproteins that are believed to have atheroprotective properties that reduce the risk of cardiovascular disease (CVD). Current evidence suggests that the physicochemical and functional features of HDLs may play a key role in the pathogenesis of atherosclerosis. Objective: We aimed to assess the impact of MAFLD on cholesterol efflux capacity (CEC) in adolescents with DM2. Design: A cross-sectional study. Setting: Attention clinic for Children with Diabetes of the Hospital Infantil de México Federico Gómez. Patients or other participants: This study included a total of 70 adolescents, 47 of which had DM2 and 23 were healthy individuals. Interventions: The presence of MAFLD was determined by MR spectroscopy with proton density fat fraction. We compared the distribution of HDL subtypes (HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c) and the chemical composition of HDLs (total protein, triglycerides, phospholipids, cholesteryl esters, and free cholesterol). HDL functionality was determined by the CEC, measuring the fluorescent cholesterol efflux from J774 macrophage cells. Main outcome measures: We were expecting to observe a decrease in HDL efflux capacity in adolescents with type 2 diabetes and MAFLD. Results: In our study, we observed a prevalence of MAFLD in 66% of adolescents with DM2, similar to that reported in other international studies (60%-80%). In the population with DM2 and MAFLD, we did not observe a decrease in CEC. Initially we found a slight elevation of CEC in adolescents with DM2, however, with the increase in liver fat, a little decrease is observed, which could explain a probable metabolic phenomenon, since the physicochemical composition and distribution of the particles is associated with the percentage of liver fat. A positive correlation between the percentage of liver fat and the concentration of HDL2b ( Conclusions: In this group of adolescents with DM2, the presence of MAFLD was not associated with CEC; however, it is associated with abnormalities in the distribution and lipid composition of HDL particles. The momentum generated by the original proposal for MAFLD in the adult population and following the recommendations for pediatric MAFLD will be a step forward in helping to study the impact of MAFLD on the atheroprotective properties of HDL in the pediatric population.

Indexed as

adolescentscholesterol-effluxdiabetesHDLlipidsMAFLD

Identifiers

PMID39776642
PMCPMC11703661

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.